Looking forward in 2023, our first clinical day in the new offices at 618 West Fulton Street, Chicago, Illinois 60661 is Tuesday, January 10. The number to use to schedule a visit is (312) 475-1893. Our Glenview office is scheduled to open in March of this year. The same office number will allow for the scheduling of an appointment in either location.
As readers of this Blog are aware, we frequently refer to ourselves as an “Evidence Based “practice. With the move, we have upgraded our ability to monitor results and make sure we stay at the forefront of Cellular Orthopedics, a needle and not a knife.
Mesenchymal stem cells (MSCs) were named by Dr. Arnold Caplan in his publication titled Mesenchymal Stem Cells, Journal of Orthopedic Research in 1991. MSCs are adult stem cells that can be isolated from different sources including bone marrow, fat/adipose tissue, and umbilical cord tissue. Scientists have found the greatest concentration of stem cells in the body to be in fat tissue. These cells could then be culture expanded (grown and multiplied) and packaged as doses for administration for conditions such as osteoarthritis and other inflammatory diseases. At this time, the FDA does not sanction the use of umbilical cord tissue as a source of stem cells or culturing of stem cells unless it is under the auspices of an FDA-approved and monitored clinical trial.
MSCs are designed to function at the site where any injury has occurred. They communicate with the immune system instructing it among many things to depress inflammation while also sending the body signals to regenerate healthy tissue and heal. MSCs are masters of producing the factors that make connections between cells so that the body can restore its natural structure and function. The ability of MSCs to regenerate tissue within the body is not because it has the capacity to replicate itself and create another cell but, rather, of its stimulatory effect (function of providing a supportive microenvironment) on the body to naturally regenerate its own cells.
At the start of this new year, I am introducing a clinical study using micro-fractured adipose tissue (fat), obtained via min liposuction from your abdomen. Until Personalized Stem Cells receives FDA approval for a Clinical Trial allowing us to use culture expanded adipose-derived stem cells, micro-fractured fat allows communication with the immune system instructing it among many things to depress inflammation while also sending the body signals to regenerate healthy tissue and heal. For the time being, the study will seek enrollment of patients with problematic knees and shoulders. As this is not a clinical trial but rather a clinical study, there is no financial sponsor; however, I will be offering a generous discount on the cost of care for those willing to participate.
Interested patients should call (312) 475-1893 to schedule a consultation. You may visit my website at www.sheinkopmd.com. To learn more about micro fractured adipose tissue, visit www.jointechlabs.com.